A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

NCT05919823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline and Trospium Chloride Capsules
DRUG: Placebo

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Collaborators

[object Object]